Estimation of Lifetime Costs Among Insured Persons with HIV in the United States
Among a sample of primarily commercially insured US adults, HIV conferred an estimated incremental LTC difference of over $2.4 million (undiscounted) and $1.1 million (discounted), with annual costs being six to seven times higher for PWH compared to non-HIV persons.
Authors
- Riddhi Doshi (ORCID: https://orcid.org/0000-0002-1439-1511)
- Mary J. Christoph (ORCID: https://orcid.org/0000-0001-8769-9931)
- Vamshi Ruthwik Anupindi (ORCID: https://orcid.org/0000-0002-0385-8657)
- Woodie Zachry
- Jason Yeaw (ORCID: https://orcid.org/0009-0001-2204-3701)
- Xiaoyu Zhou (ORCID: https://orcid.org/0000-0002-9840-9159)
- Cassidy Trom
- Joshua Cohen (ORCID: https://orcid.org/0000-0002-0180-5367)
- Megan Chen
- Paresh Chaudhari
Institutions
- Tufts University (US)
- IQVIA (United States) (US)
- Gilead Sciences (United States) (US)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1007/s41669-025-00584-0
- Citations
- 6
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 8.38
Funders
- Gilead Sciences